• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
PublishGo to AppAI Superconnector
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form 4 filed by Director Dalal Anupam

    6/16/25 4:52:43 PM ET
    $WHWK
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $WHWK alert in real time by email
    SEC FORM 4 SEC Form 4
    FORM 4 UNITED STATES SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549

    STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

    Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
    or Section 30(h) of the Investment Company Act of 1940
    OMB APPROVAL
    OMB Number: 3235-0287
    Estimated average burden
    hours per response: 0.5
      
    Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
      
    Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
    1. Name and Address of Reporting Person*
    Dalal Anupam

    (Last) (First) (Middle)
    C/O WHITEHAWK THERAPEUTICS, INC.

    (Street)
    MORRISTOWN NJ 07960

    (City) (State) (Zip)
    2. Issuer Name and Ticker or Trading Symbol
    Whitehawk Therapeutics, Inc. [ WHWK ]
    5. Relationship of Reporting Person(s) to Issuer
    (Check all applicable)
    X Director 10% Owner
    Officer (give title below) Other (specify below)
    3. Date of Earliest Transaction (Month/Day/Year)
    06/12/2025
    4. If Amendment, Date of Original Filed (Month/Day/Year)
    6. Individual or Joint/Group Filing (Check Applicable Line)
    X Form filed by One Reporting Person
    Form filed by More than One Reporting Person
    Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
    1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year) 2A. Deemed Execution Date, if any (Month/Day/Year) 3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
    Code V Amount (A) or (D) Price
    Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
    (e.g., puts, calls, warrants, options, convertible securities)
    1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year) 3A. Deemed Execution Date, if any (Month/Day/Year) 4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year) 7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
    Code V (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares
    Stock Option (right to buy) $2.04 06/12/2025 A 40,006 (1) 06/12/2035 Common Stock 40,006 $0 40,006 D
    Explanation of Responses:
    1. Subject to the Reporting Person continuing to be a Service Provider (as defined in the Issuer's 2021 Equity Incentive Plan) through such applicable date, one hundred percent (100%) of the shares subject to the option shall vest on the earlier of (i) the one (1) year anniversary of the Date of Grant or (ii) the day immediately prior to the next annual meeting of stockholders following the Date of Grant. "Date of Grant" shall mean June 12, 2025.
    Remarks:
    Exhibit 24 - Power of Attorney
    /s/ Stephen Rodin, as Attorney-in-Fact 06/16/2025
    ** Signature of Reporting Person Date
    Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
    * If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
    ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
    Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
    Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
    Get the next $WHWK alert in real time by email

    Crush Q3 2025 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $WHWK

    DatePrice TargetRatingAnalyst
    More analyst ratings

    $WHWK
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    SEC Form 4 filed by Director Zhao Baiteng

    4 - Whitehawk Therapeutics, Inc. (0001422142) (Issuer)

    6/17/25 8:10:46 PM ET
    $WHWK
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 4 filed by Director Desai Neil

    4 - Whitehawk Therapeutics, Inc. (0001422142) (Issuer)

    6/17/25 4:37:32 PM ET
    $WHWK
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 4 filed by Director Hirmand Mohammad

    4 - Whitehawk Therapeutics, Inc. (0001422142) (Issuer)

    6/16/25 4:58:37 PM ET
    $WHWK
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $WHWK
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Tempus Announces Collaboration with Whitehawk Therapeutics to Advance Biomarker-Driven Oncology Research

    Tempus AI, Inc. (NASDAQ:TEM), a technology company leading the adoption of AI to advance precision medicine, today announced a multi-year collaboration with Whitehawk Therapeutics, Inc. (NASDAQ:WHWK), an oncology therapeutics company applying advanced technologies to established tumor biology to efficiently deliver improved antibody drug conjugates (ADC) cancer treatments. The collaboration aims to leverage Tempus' proprietary real-world dataset to advance biomarker-driven research and support the development of Whitehawk Therapeutics' oncology pipeline. Under the agreement, Whitehawk Therapeutics will apply Tempus' de-identified multimodal database to support the biotech's clinical trial

    10/16/25 8:30:00 AM ET
    $TEM
    $WHWK
    Computer Software: Programming Data Processing
    Technology
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Whitehawk Therapeutics to Participate in Upcoming Investor Conferences

    MORRISTOWN, N.J., Sept. 2, 2025 /PRNewswire/ -- Whitehawk Therapeutics, Inc. (NASDAQ:WHWK), an oncology therapeutics company applying advanced technologies to established tumor biology to efficiently deliver improved ADC cancer treatments, announced today that the Company's president and CEO, Dave Lennon, PhD, will participate in a fireside chat during the following upcoming investor conferences in New York City, NY: Morgan Stanley 23rd Annual Global Healthcare Conference on Monday, September 8, 2025. Fireside chat at 4:50 PM ET.H.C. Wainwright 27th Annual Global Investment Conference on Tuesday, September 9, 2025. Fireside chat at 3:30 PM ET.A live webcast of the fireside chat events can be

    9/2/25 8:00:00 AM ET
    $WHWK
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Whitehawk Therapeutics Reports Second Quarter 2025 Financial Results and Recent Highlights

    MORRISTOWN, N.J., Aug. 7, 2025 /PRNewswire/ -- Whitehawk Therapeutics, Inc. (NASDAQ:WHWK), an oncology therapeutics company applying advanced technologies to established tumor biology to efficiently deliver improved ADC cancer treatments, today announced financial results for the second quarter ended June 30, 2025, and provided recent corporate progress. "We're pleased with the progress made in Q2 to advance our ADC portfolio and remain on track to file INDs for our first two programs – HWK-007 and HWK-016 – by year-end 2025, with the third program, HWK-206, to follow in mid-2026," said Dave Lennon, PhD, President and CEO of Whitehawk Therapeutics. "We believe we are well-positioned to advan

    8/7/25 8:00:00 AM ET
    $WHWK
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $WHWK
    SEC Filings

    View All

    SEC Form 10-Q filed by Whitehawk Therapeutics Inc.

    10-Q - Whitehawk Therapeutics, Inc. (0001422142) (Filer)

    8/7/25 4:25:08 PM ET
    $WHWK
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Whitehawk Therapeutics Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

    8-K - Whitehawk Therapeutics, Inc. (0001422142) (Filer)

    8/7/25 8:03:57 AM ET
    $WHWK
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 8-K filed by Whitehawk Therapeutics Inc.

    8-K - Whitehawk Therapeutics, Inc. (0001422142) (Filer)

    6/13/25 4:39:10 PM ET
    $WHWK
    Biotechnology: Pharmaceutical Preparations
    Health Care